News
PET/CT accurately predicts MCL stage
The promising results suggest bone marrow involvement could be assessed without a biopsy.
News
Ibrutinib stacks up well on safety in pooled analysis
The study looked at ibrutinib safety for CLL/SLL and MCL across four studies.
News
FDA issues guidance for hemophilia gene therapy development
The agency issued three disease-specific gene therapy guidances, including for retinal disorders and rare diseases.
News
Pfizer launches phase 3 gene therapy study in hemophilia B
Fidanacogene elaparvovec is an investigational gene therapy aimed at allowing hemophilia B patients to live free of routine infusions.
News
Lab results may help predict complications in ALL treatment
Researchers identified factors that predict which pediatric ALL patients were likely to have a longer hospital stay after induction chemotherapy...
News
Promising phase 3 results for ixazomib in multiple myeloma
The drug met the primary endpoint in a phase 3 study of maintenance therapy after stem cell transplant.
News
European Medicines Agency recommends CAR T-cell approvals
The therapies must be approved by the European Commission before they can be marketed to patients.
News
Bortezomib plus vorinostat shows modest response in MCL
The phase 2 trial looked at the combination in mantle cell lymphoma and diffuse large B-cell lymphoma patients.
News
Combo treatment under review for Waldenstrom macroglobulinemia
The FDA has granted priority review to the combination of ibrutinib plus rituximab.
News
Hemophilia adherence tied to perception of disease
Adherence to prophylaxis is generally high, but quality of life and disease coping matter.
News
British good practice paper offers MCL diagnosis pearls
The good practice paper includes new information on pathology and use of PET/CT scanning in staging of disease.
News
Emicizumab gets priority review for hemophilia A without inhibitors
The Food and Drug Administration is expected to make an approval decision on emicizumab in October 2018.
News
FDA grants priority review to first-line SAA treatment
Eltrombopag is being evaluated for first-line treatment of severe aplastic anemia with standard immunosuppressive therapy.
News
Overcoming TP53 mutation proves difficult in MCL
A new study shows disappointing results for the addition of lenalidomide to chemoimmunotherapy regimens.